**COVID-19**

**MitraClip Insertion to Hasten Recovery from Severe COVID-19**

Vinayak Nagaraja, MBBS, MS, MMed (Clin Epi), FRACP, Tom Kai Ming Wang, MBChB, MD (Res), FRACP, Serge C. Harb, MD, and Samir R. Kapadia, MD, Cleveland, Ohio

**INTRODUCTION**

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has affected 188 countries worldwide, with a global death toll of more than 1 million.1 The severe form of the disease is more commonly seen in the elderly and in patients with multiple comorbidities and carries a bad prognosis.1,2 Patients with valvular heart disease are also at increased risk for adverse outcomes from COVID-19.3 The MitraClip (Abbott Vascular, Santa Clara, CA) has been approved for functional as well as degenerative mitral regurgitation in the United States.4-8 We describe the case of a patient with severe COVID-19 with multiple complications who underwent MitraClip implantation to treat refractory pulmonary edema to hasten recovery from this lethal disease.

**CASE PRESENTATION**

A 67-year-old man with asymptomatic Barlow’s syndrome developed COVID-19. Subsequently his prolonged hospital stay (>2 months) was complicated by respiratory failure necessitating tracheostomy, acute renal failure necessitating hemodialysis, a large stage 4 decubitus ulcer, and protein energy malnutrition. All these complications were a result of COVID-19. The patient had difficulty weaning off ventilation because of recurrent pulmonary edema and prolonged sessions of renal replacement therapy. His other major issue was a large decubitus ulcer that necessitated debridement and colorectal surgery to provide a diverting colostomy. Clinical examination was significant for jugular venous distension, bibasilar crackles, and a grade 5 holosystolic murmur at the apex. Electrocardiography demonstrated new-onset atrial fibrillation with a rapid ventricular response. On transesophageal echocardiography (Video 1), the patient was found to have severe mitral valve regurgitation due to P2 prolapse and flail that was likely related to myxomatous degenerative disease. The transmitral gradient was 3 mm Hg. The left and right ventricles were normal in size, with preserved systolic function and moderate pulmonary hypertension (Swan-Ganz catheter mean pulmonary arterial pressure 50 mm Hg, right atrial pressure 10 mm Hg). The patient subsequently underwent transesophageal echocardiography–guided direct-current cardioversion along with therapeutic anticoagulation with intravenous unfractionated heparin. There was no evidence of infective endocarditis or thrombus in the left atrial appendage. The patient was started on intravenous sodium nitroprusside and Swan-Ganz-guided therapy. Chest computed tomography showed large bilateral pleural effusions with adjacent atelectasis, diffuse ground-glass attenuation, pulmonary edema, and bronchiectasis of the peripheral airways (Video 2). In view of refractory pulmonary edema, the patient was scheduled for MitraClip insertion.

All donning and doffing procedures for COVID-19 were undertaken. While implanting the clips under general anesthesia, ventilation was transiently held. This was not well tolerated by the patient because of significant lung damage due to COVID-19. MitraClip placement was performed swiftly and efficiently. Using fluoroscopy and transesophageal echocardiography, two MitraClip NTW devices were successfully placed across the A2/P2 and A1/P1 scallops (Video 3, Figure 1). Ventilation improved remarkably after placement of the clips. Mitral regurgitation was reduced to trivial, with an acceptable gradient of 4 mm Hg (Video 4). Mean left atrial pressure was significantly reduced from 28 to 16 mm Hg, with a systolic blood pressure of 80 mm Hg. After the procedure, the patient’s ventilation improved, with resolution of pulmonary edema. Two days later he underwent successful excisional debridement of his stage 4 pressure ulcer and open formation of a diverting end (loop) sigmoid colostomy. Four

From the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.

Keywords: SARS-CoV-2, MitraClip, Mitral regurgitation

Conflicts of interest: The authors reported no actual or potential conflicts of interest relative to this document.

Special Note: In response to this year’s global health crisis, the American Society of Echocardiography Foundation, with the help of our generous donors, raised more than $5,000 for COVID-19-related aid in May. The American Society of Echo¬cardiography Foundation is proud to cover the processing fee for this report from these funds.

Copyright 2020 by the American Society of Echocardiography. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

2468-6441

https://doi.org/10.1016/j.case.2020.10.004

Figure 1 Successful placement of two clips across the mitral valve.
weeks later the patient was discharged to a long-term care hospital. Chest computed tomography performed 1 month later revealed reduction in pleural effusion and resolution of pulmonary edema (Video 5).

DISCUSSION

The true impact of severe valvular heart disease in patients with COVID-19 has not described in the literature so far.3,9,10 Nevertheless, it is clear that patients with severe valvular heart disease often tend to be multimorbid and frail and have a higher mortality rate compared with the normal population.3 With future data and research, it will become clear that the prognosis of patients with the combination of COVID-19 and severe valvular heart disease will be poor.3 The acute hemodynamic effects of MitraClip intervention have been well documented by the EVEREST trial investigators.11 MitraClip implantation leads to increases in cardiac output (from 5.0 ± 2.0 to 5.7 ± 1.9 L/min, P = .003) and forward stroke volume (from 57 ± 17 to 65 ± 18 mL, P < .001). Decreases in systemic vascular resistance (from 1,226 ± 481 to 1,004 ± 442 dyn · s/cm², P < .001), left ventricular end-diastolic pressure (from 11.4 ± 9.0 to 8.8 ± 5.8 mm Hg, P = .016), and left ventricular end-diastolic volume (from 172 ± 37 to 158 ± 38 mL, P < .001) were noted after MitraClip placement.11 A post hoc subgroup analysis of the EVEREST I feasibility trial and EVEREST II pivotal trial demonstrated that MitraClip procedures performed in patients with hemodynamic decompensation resulted in significant reductions in left ventricular end-diastolic pressure (from 20 ± 5 to 13 ± 5 mm Hg, P = .002) and mean pulmonary capillary wedge pressure (from 20 ± 4 to 16 ± 5 mm Hg, P = .001) and a significant increase in cardiac index (from 2.0 ± 0.5 to 2.5 ± 5 L/min/m², P < .001).12

CONCLUSION

This is the first reported case of MitraClip insertion in a patient with severe COVID-19. The hemodynamic changes after MitraClip placement assisted in the patient’s recovery by reducing left atrial pressures, resolving pulmonary edema, and allowing other necessary medical procedures that were on hold to take place. We are certain that this will be a more frequent occurrence during the coming year as cases of COVID-19 continue to surge across the United States.

SUPPLEMENTARY DATA

Supplementary data related to this article can be found at https://doi.org/10.1016/j.case.2020.10.004.

REFERENCES

1. Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. N Engl J Med. Available at: https://www.nejm.org/doi/full/10.1056/NEJMcp2009575. Accessed October 23, 2020.
2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature 2020;584:430-6.
3. Chung CJ, Nazif TM, Wobitsch M, Hakemi E, Lebehn M, Brandwein R, et al. Restructuring structural heart disease practice during the COVID-19 pandemic: JACC review topic of the week. J Am Coll Cardiol 2020;75:2974-83.
4. Obadia J-F, Messika-Zeitoun D, Leurent G, Jung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:2297-306.
5. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395-406.
6. Glower DD, Kar S, Trento A, Lim DS, Bajwa T, Quesada R, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol 2014;64:172-81.
7. Mahabir CA, DeFilippis EM, Aggarwal S, Bath A, Qamar A, Patel NK, et al. The first 4 years of postmarketing safety surveillance related to the MitraClip device: a United States Food and Drug Administration MAUDE experience. J Invasive Cardiol 2020;32:E130-2.
8. Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann HC, et al. 4-Year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol 2013;62:317-28.
9. Shah PB, Welt FGP, Mahmud E, Phillips A, Kleiman NS, Young MN, et al. Triage considerations for patients referred for structural heart disease intervention during the COVID-19 pandemic: an ACC/SCAI position statement. Catheter Cardiovasc Interv 2020;6:28910.
10. Harjai KJ, Aggarwal S, Bauch T, Bernardi M, Casale AS, Green S, et al. Coronary and structural heart disease interventions during COVID-19 pandemic: a road map for clinicians and health care delivery systems. Cardiovasc Revasc Med 2020;10:3062-6.
11. Siegel RJ, Biner S, Rafique AM, Rinaldi M, Lim S, Fail P, et al. The acute hemodynamic effects of MitraClip therapy. J Am Coll Cardiol 2011;57:1658-65.
12. Biner S, Siegel RJ, Feldman T, Rafique AM, Trento A, Whitlow P, et al. Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. Eur J Heart Fail 2012;14:939-45.